Overview
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Description
The proposed project will enroll a total of 614 women.
Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only.
Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.
Eligibility
Mayo Clinic Rochester-
Inclusion Criteria:
- Women who previously participated in this study
- Currently aged 60 years and older
- More than six months post chemotherapy or major surgery requiring general anesthesia
- Willing and able to sign informed consent
Exclusion Criteria:
- Not able to read and speak English
- In hospice
- Claustrophobic
- If undergoing Tau imaging, cannot have QT Prolongation
Mayo Clinic Jacksonville-
Inclusion Criteria:
- African American Women
- Currently aged 60 years and older
- More than six months post chemotherapy or major surgery requiring general anesthesia
- Willing and able to sign informed consent
Exclusion Criteria:
- Not able to read and speak English
- In hospice
- Claustrophobic
- If undergoing Tau imaging, cannot have QT Prolongation